November 22, 2009

FDA Byetta (exenatide) Associated with Risk of Renal Failure

FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. Byetta, an incretin-mimetic, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Related Articles:

Acute Kidney Injury, General Nephrology

Comments are closed.